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this paper that reviews the experience in Pasadena with distal revas-
cularization-interval ligation (DRIL) for the treatment of vascular
access-induced ischemia. The clinical results the authors achieved
are similar to that published elsewhere including our own extensive
experience with this procedure in Tucson. The risk factors identi-
ﬁed by the authors similarly correlate with previous studies. Inter-
estingly, the authors reported diabetes in only 83% of the patients
with signiﬁcant steal. In my own experience with more than 100
DRIL procedures, I have seen clinically signiﬁcant steal in only
two patients without diabetes. Similar to other reports on the
DRIL procedure, the authors demonstrated that the outcomes
of relieving ischemia while preserving access were achieved with
acceptable durability. The physiology of clinically signiﬁcant steal
remains complex. I have a number of questions for the authors:
1. Given their experience, what do the authors recommend pre-
emptively to minimize this problem? What is the minimum
workup before access construction that the authors perform
and how does that impact their algorithm for access selection?
2. How do the authors assess their patients intraoperatively at the
time of access creation to determine if ischemia is going to be
a problem postoperatively? How do the authors handle an
ischemic hand at the conclusion of access construction?
3. Prior to proceeding with treatment for access-induced
ischemia, what workup do the authors perform on the patient?
How does the access ﬂow impact the decision to do a DRIL
versus a banding, RUDI, proximalization of arterial inﬂow,
or ligation? Gary Gelbﬁsh, a prominent access surgeon from
Brooklyn, stratiﬁes the treatment algorithm for ischemia on
the basis of the ﬂow rate through the access. Do the authors
have any thoughts in this regard?
4. Do the authors have any recommendations for patients with
isolated early neurological deﬁcits? How do the authors distin-
guish ischemic monomelic neuropathy, steal, and simple neu-
ropraxia related to the trauma adjacent to the nerves fromthe access placement? These are particularly challenging
patients as many of them have only physiological steal whose
symptoms will resolve over time.
5. For high-ﬂow ﬁstulas I have started using ﬂow-based banding
to treat ischemic steal. This technology allows for the intrao-
perative measurement of both direction and quantity of ﬂow
with the end points of banding evolving into maintaining
adequate volume ﬂow through the access while restoring ante-
grade ﬂow in the brachial artery distal to the access. Given their
experience, do the authors have any thoughts on this
technique?
I thank the program committee for allowing me the privilege
of discussing this paper.
Dr Steven G. Katz. Dr Berman, thank you for your insightful
remarks and thoughtful questions, which I will attempt to answer
in order. Before access creation we routinely obtain vein mapping
and liberally employ duplex scanning of the upper extremity donor
arteries if there is any question of an inﬂow problem. While in the
operating room, we check for Doppler signals in the radial and
ulnar arteries and, if absent, consider immediate performance of
a DRIL procedure. Prior to performance of a DRIL procedure,
we routinely perform noninvasive testing to look for reversal of
ﬂow in the brachial artery and to demonstrate ﬂow augmentation
with ﬁstula compression. In addition, we perform a ﬁstulogram to
evaluate arterial inﬂow and venous outﬂow and map the greater
saphenous vein to evaluate its suitability as a conduit. We have
not measured ﬁstula ﬂow and have no experience with this ﬂow
algorithm. The etiology of early neurological deﬁcits is often difﬁ-
cult to discern. We base our treatment on the severity of symptoms
observed, rather than attempt to distinguish between types of
nerve injury. If a severe deﬁcit is observed we rapidly proceed to
DRIL or ﬁstula ligation. We have no experience with the banding
techniques described by Dr Berman, but ﬁnd them intriguing and
will follow his results with interest. Once again I thank Dr Berman
for his comments and the society for the privilege of the ﬂoor.
